Development and validation of a drug adherence index for COPD
| Autor: | Tim Bancroft, Craig Schilling, Ami R Buikema, Richard H. Stanford, Lindsay G S Bengtson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty MEDLINE Pharmaceutical Science Pharmacy Medicare Advantage Logistic regression Risk Assessment Medication Adherence Pulmonary Disease Chronic Obstructive Health care medicine Humans Aged Retrospective Studies Aged 80 and over business.industry Health Policy Mortality rate Retrospective cohort study Middle Aged United States Bronchodilator Agents Logistic Models Pharmaceutical Services Family medicine Inclusion and exclusion criteria Medicare Part C Female business Administrative Claims Healthcare |
| Zdroj: | Journal of Managed Care & Specialty Pharmacy. 27:198-209 |
| ISSN: | 2376-1032 2376-0540 |
| DOI: | 10.18553/jmcp.2021.27.2.198 |
| Popis: | BACKGROUND: Inhaled medications are the mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite their importance, adherence to these medications is low. Low adherence is linked to increased exacerbation rates, mortality rates, health care utilization, and, ultimately, increased costs. A drug adherence index (DAI) is a predictive modeling tool that identifies patients most likely to change adherence status so that they can be targeted for support programs. Optum has previously developed DAI tools for diabetes, hypertension, and high cholesterol. In this study, a COPD-specific DAI was developed. This DAI tool could be used to better target medication adherence support in patients with COPD, aiming to increase adherence. OBJECTIVES: To develop a COPD-specific DAI using (a) enrollment, medical, and pharmacy variables and (b) only enrollment and pharmacy variables for potential application to pharmacy benefit managers and pharmacy plans. METHODS: This was a retrospective observational study using health care claims among Medicare Advantage with Part D beneficiaries with COPD in the United States. Potential predictors of adherence were measured during a 1-year baseline period. The adherence outcome was measured during a subsequent 1-year at-risk period. Adherence to long-acting bronchodilators was defined as a proportion of days covered (PDC) ≥80%. Nonadherence was defined as a PDC of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|